Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

OBJECTIVE: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA). METHODS: This was a phase II, randomised, placebo-controlled, double-blind trial of adults with active PsA (≥3 swollen and ≥3 tender joints and C reacti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Gladman, Dafna D, Deodhar, Atul, McGonagle, Dennis G, Nash, Peter, Boehncke, Wolf-Henning, Gottlieb, Alice, Xu, Xie L, Xu, Stephen, Hsia, Elizabeth C, Karyekar, Chetan S, Helliwell, Philip S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425189/
https://www.ncbi.nlm.nih.gov/pubmed/32665433
http://dx.doi.org/10.1136/rmdopen-2020-001217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425189/
https://www.ncbi.nlm.nih.gov/pubmed/32665433
http://dx.doi.org/10.1136/rmdopen-2020-001217

Ejemplares similares